These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1632 related items for PubMed ID: 26289836

  • 1. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH, Komm BS.
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [Abstract] [Full Text] [Related]

  • 2. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S, Komm BS.
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [Abstract] [Full Text] [Related]

  • 3. Selective estrogen receptor modulators in clinical practice: a safety overview.
    Ellis AJ, Hendrick VM, Williams R, Komm BS.
    Expert Opin Drug Saf; 2015 Jun; 14(6):921-34. PubMed ID: 25936229
    [Abstract] [Full Text] [Related]

  • 4. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV, Thomas S.
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [Abstract] [Full Text] [Related]

  • 5. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.
    Chang KC, Wang Y, Bodine PV, Nagpal S, Komm BS.
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):117-24. PubMed ID: 19914376
    [Abstract] [Full Text] [Related]

  • 6. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.
    Smith CL, Santen RJ, Komm B, Mirkin S.
    Breast Cancer Res; 2014 Jun 18; 16(3):212. PubMed ID: 25928299
    [Abstract] [Full Text] [Related]

  • 7. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators.
    Pinkerton JV, Conner EA.
    Climacteric; 2019 Apr 18; 22(2):140-147. PubMed ID: 30895900
    [Abstract] [Full Text] [Related]

  • 8. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F, Lopes P.
    Presse Med; 2002 Sep 07; 31(28):1323-8. PubMed ID: 12355995
    [Abstract] [Full Text] [Related]

  • 9. Selective estrogen modulators in menopause.
    Gambacciani M.
    Minerva Ginecol; 2013 Dec 07; 65(6):621-30. PubMed ID: 24346250
    [Abstract] [Full Text] [Related]

  • 10. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention.
    Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS.
    Endocrinology; 2008 Dec 07; 149(12):6084-91. PubMed ID: 18703623
    [Abstract] [Full Text] [Related]

  • 11. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
    Palacios S, Currie H, Mikkola TS, Dragon E.
    Maturitas; 2015 Apr 07; 80(4):435-40. PubMed ID: 25684082
    [Abstract] [Full Text] [Related]

  • 12. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.
    Stovall DW.
    Curr Opin Investig Drugs; 2010 Apr 07; 11(4):464-71. PubMed ID: 20336595
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
    Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G.
    Fertil Steril; 2009 Sep 07; 92(3):1045-1052. PubMed ID: 19635616
    [Abstract] [Full Text] [Related]

  • 14. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ, Gillespie JA.
    Postgrad Med; 2017 Apr 07; 129(3):340-351. PubMed ID: 28132583
    [Abstract] [Full Text] [Related]

  • 15. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.
    Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA.
    Endocrinology; 2009 Apr 07; 150(4):1897-903. PubMed ID: 19022889
    [Abstract] [Full Text] [Related]

  • 16. Tissue selective estrogen complex (TSEC): a review.
    Pickar JH, Boucher M, Morgenstern D.
    Menopause; 2018 Sep 07; 25(9):1033-1045. PubMed ID: 29533367
    [Abstract] [Full Text] [Related]

  • 17. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.
    Lewiecki EM.
    Expert Opin Investig Drugs; 2007 Oct 07; 16(10):1663-72. PubMed ID: 17922629
    [Abstract] [Full Text] [Related]

  • 18. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.
    Pinkerton JV, Komm BS, Mirkin S.
    Climacteric; 2013 Dec 07; 16(6):618-28. PubMed ID: 23805785
    [Abstract] [Full Text] [Related]

  • 19. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.
    Pickar JH, Yeh IT, Bachmann G, Speroff L.
    Fertil Steril; 2009 Sep 07; 92(3):1018-1024. PubMed ID: 19635613
    [Abstract] [Full Text] [Related]

  • 20. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.
    Rossini M, Lello S, Sblendorio I, Viapiana O, Fracassi E, Adami S, Gatti D.
    Drug Des Devel Ther; 2013 Sep 07; 7():601-10. PubMed ID: 23901263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.